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Agonist bias occurs when different ligands produce distinct signalling outputs when acting at
the same receptor. However, its physiological relevance is not always clear. Using primary
human cells and gene editing techniques, we demonstrate endogenous agonist bias with
physiological consequences for the calcitonin receptor-like receptor, CLR. By switching the
receptor-activity modifying protein (RAMP) associated with CLR we can “re-route” the
physiological pathways activated by endogenous agonists calcitonin gene-related peptide
(CGRP), adrenomedullin (AM) and adrenomedullin 2 (AM2). AM2 promotes calcium-
mediated nitric oxide signalling whereas CGRP and AM show pro-proliferative effects in
cardiovascular cells, thus providing a rationale for the expression of the three peptides. CLR-
based agonist bias occurs naturally in human cells and has a fundamental purpose for its
existence. We anticipate this will be a starting point for more studies into RAMP function in
native environments and their importance in endogenous GPCR signalling.
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G protein-coupled receptors (GPCRs) form the largestprotein family in the human genome. Approximately 30%of marketed drugs target these receptors and therefore
understanding their signalling pathways is not simply an aca-
demic exercise. For many years it had been incorrectly assumed
that agonist-occupied GPCRs signalled through a single pathway
to elicit their response. However, there is now overwhelming
evidence to suggest that many GPCRs exist in multiple receptor
conformations and can elicit numerous functional responses,
both G protein- and non-G protein-dependent. Furthermore,
different agonists, acting at the same receptor have the potential
to activate different signalling pathways to varying extents; a
concept referred to as biased agonism or signalling bias1,2. This
can explain why there is apparent duplication amongst endo-
genous agonists, particularly for peptides. While the therapeutic
promise of biased agonists is obvious:3 it allows design of ligands
that actively engage with one beneficial signalling outcome while
reducing the contribution from those that mediate more unde-
sirable effects, it is not without controversy. For example, recent
doubt has been cast on validity of developing synthetic biased
agonists against the μ-opioid receptor—a GPCR considered the
trailblazer for therapeutic potential of biased agonism4. Thus,
further investigations into the role of agonist bias and its phy-
siological importance, particularly its relevance to endogenous
agonists, are required to bridge the gap between heterologous
studies and in-vivo investigations.
While there are many well-studied GPCRs that exhibit sig-
nalling bias, including the aforementioned μ-opioid receptor, we
have focused upon the calcitonin-like receptor (CLR) since it
couples to multiple G proteins and β-arrestins. Importantly, when
co-expressed with one of three receptor-activity modifying pro-
teins, (RAMPs), it can be activated by distinct endogenous ago-
nists; calcitonin-gene related polypeptide (CGRP),
adrenomedullin (AM) and adrenomedullin 2/intermedin (AM2).
This makes it a good system to investigate the role of bias for
endogenous ligands. CGRP, an abundant neuropeptide, is the
most potent microvascular vasodilator known. While it is thought
to be cardioprotective, it has also been implicated in diseases such
as migraine5. AM is released by the vascular endothelium and is a
potent vasodilator that can modulate vascular tone, it is involved
in angiogenesis, and is elevated in some cancers and heart
failure6–8. AM2 is also a vasodilator and highly expressed in the
heart and vasculature9,10. It can cause sympathetic activation,
have antidiuretic effects, and is upregulated in cardiac hyper-
trophy and myocardial infarction11.
Molecularly, CLR and its close relative, the calcitonin receptor,
are classical class B1 GPCRs. CLR is pleiotropically coupled,
predominately activating Gs although there are reports of cou-
plings to both Gi/o and Gq/112,12 families. These Gα subunits
promote activation/inhibition of adenylyl cyclase and phospho-
lipase Cβ to generate intracellular second messengers including
cAMP and mobilise intracellular Ca2+ (Ca2+i) which then acti-
vate their respective intracellular signalling cascades. Beyond the
Gα subunits CLR has been reported to couple to β-arrestins13
inducing internalisation, although it has been suggested that this
interaction can also lead to its own signalling events possibly
promoting cell proliferation14. Despite this high potential for
agonist-induced pleiotropy, CLR remains most closely associated
with adenylyl cyclase activation and generation of cAMP. It is
unknown whether this is representative of CLR’s true signalling
pattern in the endogenous setting.
Additional complexity is added to the pharmacology of the
CLR since it has an absolute requirement for the formation of a
heterodimer with a RAMP15,16. In overexpression studies, each of
the three RAMPs has been shown to differentially influence the
affinity and agonist bias of the CGRP family of peptides at the
CLR17,18. CLR in complex with RAMP1 generates the CGRP
receptor since CGRP has been demonstrated to be the most
potent of the three agonists at this receptor for generation of
cAMP. Likewise, CLR-RAMP2 generates the adrenomedullin 1
(AM1) receptor (AM is the most potent at this receptor) and
CLR-RAMP3 produces the AM2 receptor (here AM and AM2 are
equipotent). To date, the physiological role and cognate receptor
for AM2 remain unknown. While there is an abundance of evi-
dence of GPCR signalling bias in recombinant cell systems, and in
this case, CLR-mediated bias12,19, documented examples using
natural agonists and endogenously expressed human receptors
are currently lacking. We wished to ascertain whether signalling
bias at the CLR occurs in primary cells and whether it plays a role
in cellular function. We chose to focus on RAMP1 and RAMP2 as
the CGRP and AM1 receptors are the best described.
Using human endothelial cells which endogenously express the
AM1 receptor, we demonstrate that biased agonism is present
and has a fundamental role in the function of peptide hormones
acting on primary human cells. Moreover, through deletion of the
endogenous RAMP2 and replacing it with RAMP1, we highlight
that not only is the RAMP essential for CLR function and CGRP
peptide family signalling in primary cell systems but that RAMPs
direct the pattern of agonist bias observed. Furthermore, we
document previously unreported actions for the CGRP-based
peptide agonists; AM2 emerges as an agonist uniquely biased to
elevate calcium-mediated nitric oxide (NO) signalling while both
CGRP and AM display distinct pro-proliferative effects in car-
diovascular cells. The work we describe here reveals that GPCR
agonist bias occurs naturally in human cells and plays funda-
mentally important physiological roles in providing unique
functions to endogenous agonists.
Results
Endothelial cells exclusively express functional AM1 receptor.
While there are many reports of biased agonism for GPCRs in
recombinant systems (e.g.19–21), few examples have been docu-
mented in primary human cells. Given the reported roles of CGRP,
AM and AM2 in the cardiovascular system we have focussed our
studies upon these peptides, and their receptors in primary human
umbilical vein endothelial cells (HUVECs), a well-established pri-
mary human vascular endothelial cell line. Initially, we determined
that HUVECs express the AM1 receptor since we could only detect
transcripts for CALCRL (gene for CLR) and RAMP2 (Fig. 1a). This
was confirmed functionally, since when the endothelial cells were
stimulated with agonists and cAMP accumulation quantified (after
30min stimulation when the response had plateaued (Supple-
mentary Fig. 1a)), the rank order of potency was AM>AM2 >
CGRP (Fig. 1b, and Supplementary Table 1). An important factor
in confirming receptor-specific agonist bias is to ensure that com-
peting receptors are not present in the system. The closely related
calcitonin receptor not only interacts with RAMPs22 but also binds
CGRP with high affinity23. HUVECs do not appear to express the
calcitonin receptor since we were unable to detect the presence of its
transcript (Fig. 1a) or obtain a functional response upon application
of two calcitonin receptor agonists (calcitonin or amylin) (Supple-
mentary Fig. 1b). Furthermore, application of the selective AM1
receptor antagonist AM22–52 at 100 nM abolished agonist-induced
cAMP accumulation while 100 nM olcegepant (a CGRP receptor-
selective antagonist) had little effect (Supplementary Fig. 1c–h).
Thus, based upon these data, we suggested that HUVECs specifi-
cally express the AM1 receptor alone and are a useful primary cell
line with which to study potential endogenous agonist bias.
Endogenous agonist bias at the AM1 receptor. For studies of
biased agonism, it is not simply the ability of different ligands to
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activate the canonical second messenger pathway to varying
extents that is important, but their ability to differentially activate
a multitude of downstream pathways. Having established that
HUVECs express only one of the receptor-RAMP complexes
responsive to our three peptides: CGRP, AM and AM2 with the
expected potency, we next sought to quantify the extent of
endogenous agonist-induced biased signalling through the AM1
receptor at other pathways. Consistent with these previous
reports in recombinant systems19 we were able to observe
concentration-dependent increases in Ca2+i in HUVECs upon
application of AM and AM2 but little or none with CGRP
(Fig. 1c, and Supplementary Table 1). In contrast to the stimu-
lation of cAMP, AM2 was more potent than AM suggesting that a
non-cognate agonist can have a distinct and more potent effect
than the cognate agonist at certain pathways endogenously.
Importantly, all responses could be abolished with the co-
treatment of the Gαq/11/14 inhibitor YM-25489024 (Supplemen-
tary Fig. 1i) thereby confirming CLR-based pleiotropy in primary
endothelial cells.
We subsequently turned our attention to the extracellular
signal-regulated kinase 1/2 (ERK1/2) pathway (assayed after 5 min
stimulation, when the response had reached a plateau (Supple-
mentary Fig. 1j)) where we found that, again, the ‘cognate’ agonist
(AM) was not the most potent. Perhaps surprisingly, CGRP (the
agonist reported to be the least potent at cAMP production at the
AM1 receptor) was the most potent at stimulating ERK1/2
Fig. 1 CGRP family peptide signalling bias in HUVECs. a Expression of CALCR, CALCRL, RAMP1, RAMP2, and RAMP3 genes in HUVECs. Data normalised to
GAPDH expression. n= 3 independent experiments. b–f Dose–response curves were constructed for HUVECs stimulated with CGRP, AM or AM2 and the
cAMP levels quantified relative to forskolin (100 μM) (n= 7) (b), mobilisation of Ca2+i relative to ionomycin (10 μM) (n= 6) (c), intracellular ERK1/2
phosphorylation relative to PMA (10 μM) (n= 4) (d), total nitric oxide production relative to acetylcholine (10 μM) (n= 3) (e), and extent of cell
proliferation (after 72 h) relative to vector treated control and VEGF (n= 3–6) (f). Data are analysed using a three-parameter non-linear regression curve
or the operational model of receptor agonism27. g–h Signalling bias plots were calculated as ΔLog(τ/KA) (g) or ΔΔLog(τ/KA) (h) for each agonist and for
each signalling pathway. Determination of values requires normalisation to a reference agonist (AM) alone in (g), while for (h) values were normalised to
both a reference agonist (AM) and a reference pathway (cAMP). i Heatmaps representing the signalling properties between HUVEC and HUAEC cells for
potency, effector maximum and the transducer coefficient. All data represent mean ± SEM for n repeats. j Representation of the signalling outcomes as a
result of AM-mediated receptor activation in a HUVEC. Solid arrows indicate known pathways. Dashed arrows represent possible pathways.
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phosphorylation (Fig. 1d and Supplementary Table 1). Thus,
despite this being designated an AM1 receptor, it is CGRP and
not AM that produces physiologically relevant signalling via the
ERK1/2 pathway.
Physiological consequences of CGRP-based peptide agonist
bias in primary endothelial cells. As we were exploring the AM1
receptor in its native environment, we sought to discover whether
the distinct patterns of agonist bias we have observed with CGRP,
AM and AM2 were reflected further downstream in physiologi-
cally relevant outputs. We considered two potential physiological
outcomes with important therapeutic potential – the generation
of NO (a vital modulator of vascular homeostasis) and cell pro-
liferation. NO, generated through endothelial NO synthase in
endothelial cells25 promotes vasorelaxation/dilation26. In
HUVECs we observed that all three agonists could evoke NO
synthesis in the order of potencies AM2 > AM > CGRP (Fig. 1e
and Supplementary Table 1) although both AM and CGRP were
partial agonists for this pathway with the potencies closely
resembling the trends observed for Ca2+i mobilisation. Indeed, a
direct correlation between Ca2+i mobilisation and NO produc-
tion in endothelial cells was confirmed through the application of
YM-254890 which abolished all NO release (Supplementary
Fig. 1k). Such observations are consistent with the role of
increases of Ca2+i concentrations leading to endothelial NO syn-
thase stimulation25 but to the best of our knowledge, these have
not been demonstrated previously for AM2.
Beyond NO production we also measured the long-term cell
proliferation (72 h) response to the three peptides in HUVECs.
Here CGRP most potently promoted cell growth (Fig. 1f and
Supplementary Table 1). This is consistent with the data we
describe for phosphorylation of ERK1/2 suggesting proliferation is
not mediated via a cAMP-dependent pathway. This was further
corroborated by the observation that application of the non-
selective adenylyl cyclase activator forskolin induced a
concentration-dependent inhibition of cell proliferation.
Together, these data suggest that CLR exerts important cellular
effects in a Gαs-independent manner thus unveiling previously
undocumented abilities for CGRP to promote proliferation in
human cells through the AM1 receptor.
Whilst the differences in orders of potency seen with cAMP,
Ca2+i, and ERK1/2 provide strong evidence for bias, to formally
confirm this and to remove potential confounding issue of system
bias (which may arise due to the differential expression of
signalling components or cofactors in the cellular background of
choice) we fitted our HUVEC data with the operational model of
receptor agonism27 (Fig. 1g, h and Supplementary Table 1). This
gives the transducer coefficient Log(τ/KA); effectively the efficacy
of an agonist to produce a given response normalised to its
functional affinity. Agonist bias is calculated by computing ΔLog
(τ/KA); the difference in transducer coefficient for each response
compared to AM (Fig. 1h) and then the bias factor, ΔΔLog(τ/KA),
where there is a second round of normalisation with respect to
the cAMP pathway as well as AM (Fig. 1h). This analysis
reinforced the notion that AM2 is biased towards Ca2+i
mobilisation and NO production while CGRP favours pERK1/2
activation and cell proliferation.
We next wondered if the patterns of AM1 receptor bias
applied to other endothelial cell lines. We performed the same
panel of assays using human umbilical artery endothelial cells
(HUAECs) which also solely express transcripts for RAMP2 and
CALCRL (Supplementary Fig. 2a–h, Supplementary Table 1).
Indeed we were able to demonstrate a strong similarity in the
signalling profiles between the two endothelial cells across the
five different pathways (Fig. 1i and Supplementary Fig. 3a, b)
with significant correlations in potency (Supplementary Fig. 3c;
r= 0.73–95% confidence interval 0.35–0.90; p= 0.0019) and the
transducer coefficient (Fig. 1i, Supplementary Fig. 3c; τ/KA; r=
0.94–95% confidence interval 0.84 to 0.98; p < 0.0001 (to 4
decimal places)) suggesting primary endothelial cells share
common AM1 receptor signalling properties (Fig. 1j).
AM1 receptor-mediated cAMP accumulation and pERK1/2
activation exemplify agonist bias. The mechanism by which
adenylyl cyclase is regulated involves competition between Gs
(activation) and members of the Gi/o (inhibition) family of G
proteins. Semi-quantitative RT-PCR in HUVECs and HUAECs
revealed the presence of the same Gα subunits (Supplementary
Fig. 3d-e) and β-arrestins in the two cell lines. We and others
have documented how the AM1 receptor (analogous to other
class B1 GPCRs) couples to the inhibitory G proteins19,28,29
although this is often observed in overexpression systems and is
cell type dependent. Application of pertussis toxin (PTX), which
ADP-ribosylates the inhibitory G proteins (except for Gz), to the
HUVECs revealed a dose-dependent increase in cAMP accu-
mulation (Fig. 2a) and suppression of ERK1/2 phosphorylation
upon application of CGRP and AM2 but not AM (Fig. 2b). These
data, consistent with our previously reported work19 suggests that
only the non-cognate agonists (CGRP and AM2) can recruit Gi/o
proteins to the CLR, and, particularly in the case of CGRP, the
purpose of this is to bias the response away from cAMP and
towards other pathways such as pERK1/2.
This did, however, pose the question as to how AM modulates
the pERK1/2 response? Inhibition of protein kinase A had no
effect (Fig. 2c) however antagonism of Gq/11/14 signalling reduced
the potency of AM-mediated pERK1/2 activation (Fig. 2d). More
strikingly, inhibition of the exchange proteins directly activated
by cAMP 1/2 significantly attenuated both the potency (p=
0.0078) and magnitude of the maximal response (Fig. 2e). Taken
together, these data highlight the wide array of different G protein
couplings and their interlinking actions upon downstream
signalling events for the AM1 receptor. These couplings have
not been engineered so are not enhanced by overexpression
artefacts and thereby represent pure endogenous agonist bias.
RAMP isoform is essential for CLR-mediated agonist bias. One
of the advantages of using recombinant cell lines is the ability to
switch the expressed GPCR or RAMP to observe effects on
agonist bias. However, these recombinant systems do not allow
for observations of physiological bias. Thus, we next sought to
determine the effects of CGRP-based agonist bias in primary cells
where the endogenous RAMP had been switched using gene
deletion followed by lentiviral reintroduction in HUVEC cells.
We used lentiviral CRISPR-Cas9 to knockout the RAMP2 gene
from HUVECs using a pooled sgRNA strategy of using three
sgRNAs in separate lentivirus (Supplementary Fig. 4a) which
were selected using a puromycin resistance cassette (Supplemen-
tary Fig. 4b) to increase our efficiency of editing (95% as
confirmed by Sanger sequencing (Supplementary Fig. 4c, d,
Supplementary data 3, 4) and TIDE30 analysis). We confirmed
the loss of RAMP2 by qRT-PCR (Supplementary Fig. 4e)
although the expression of the Gα subunits the β-arrestins
remained consistent with wild type HUVECs (Supplementary
Fig. 4f). The rate of proliferation of the cells was unchanged
(Supplementary Fig. 4g) but as expected, there was no longer any
functional response following stimulation with all three CGRP-
based agonists (Supplementary Fig. 4h–l). We next introduced,
using lentiviral overexpression and blasticidin selection, the open
reading frame of RAMP1 into our HUVECΔRAMP2 cell line to,
in effect, switch the expressed GPCR from the AM1 receptor to
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the CGRP receptor. mRNA levels were quantified demonstrating
successful introduction of a high level of RAMP1 expression
(Fig. 3a). We next performed cAMP accumulation assays using
CGRP, AM and AM2 confirming that a functional CGRP
receptor was formed in these modified HUVECs (Fig. 3b and
Supplementary Table 2). Reassuringly, we now observed that
CGRP was the most potent agonist for the stimulation of cAMP
—as expected for a cell line expressing the CGRP receptor (CLR-
RAMP1). Perhaps more interestingly, CGRP was also the most
potent at mobilising Ca2+i (Fig. 3c and Supplementary Table 2)
and this was also the case in the associated NO production
(Fig. 3d and Supplementary Table 2). Comparison of the ERK1/2
phosphorylation (Fig. 3e and Supplementary Table 2) highlighted
that AM was now the most potent agonist; a clear switch from
wild type HUVEC cells where CGRP was the most potent. This
followed to proliferation where AM was also the most potent
ligand, although both AM2 and CGRP could also promote
growth (Fig. 3f and Supplementary Table 2) and contrasted with
the wild type HUVECs where neither could cause proliferation.
Thus switching the RAMP in the HUVEC cell line appeared to
have a dramatic effect on the agonist bias observed and the
functional consequence (Fig. 3g, h and Supplementary Table 2)—
beyond just cAMP accumulation as would be excepted. However,
it should be noted that as RAMP1 expression was high we should
be cautious in our direct comparisons between the wild type
HUVECs and our RAMP1-HUVEC cell line.
Endogenous agonist bias at the CGRP receptor in primary
human cardiac myocytes. To provide a comparison for RAMP1-
HUVEC signalling with a primary cell line we turned to primary
human cardiomyocytes (HCMs) since these cells only expressed
CLR and RAMP1 (Fig. 4a); analogous to endothelial cells, HCMs
do not express a functional calcitonin receptor (Fig. 4a and
Supplementary Fig. 5a). To confirm that the mRNA expression
translated to functional receptor expression we performed cAMP
accumulation assays for the CGRP family of peptides (Fig. 4b and
Supplementary Table 2). Here, CGRP was the most potent ago-
nist followed by AM2 and AM, a pattern consistent with the
expression of the CGRP receptor20 (also confirmed by application
of 100 nM olcegepant to inhibit cAMP accumulation for all three
agonists while 100 nM AM22–52 had little effect (Supplementary
Fig. 5b–g)). Although Gαi has previously been suggested to be
important for PTX-sensitive effects from CLR19, upon application
of PTX to HCMs we were unable to observe any change in the
potency or maximal signalling for any of the three peptide ago-
nists (Supplementary Fig. 5h–j), perhaps because the transcript
for GNAi2 (Gαi2) was lower than in the endothelial cells (Sup-
plementary Fig. 5k). In contrast to the wild type HUVECs but
analogous to the RAMP1-HUVECs cells, not only was CGRP able
to stimulate Gq/11/14-mediated-Ca2+i mobilisation in HCMs, but
it was the most potent agonist (Fig. 4c and Supplementary
Table 2). This did not directly translate to Gq/11/14-mediated-NO
production (Fig. 4d, Supplementary Fig. 5l, m and Supplementary
Table 2) since all three agonists generated responses that were less
distinct from each other. When quantifying ERK1/2 phosphor-
ylation we observed that the cognate ligand (CGRP) was not the
most potent (Fig. 4e and Supplementary Table 2). As in
HUVECs, it was the least potent ligand at cAMP accumulation
(AM) that was the most potent for ERK1/2 phosphorylation so
demonstrating that AM can produce functionally relevant sig-
nalling responses at the CGRP receptor. The order of potency for
the three agonists for ERK1/2 phosphorylation was replicated in
Fig. 2 Non-cognate Gɑ couplings at the AM1 receptor complex modulates cAMP accumulation and ERK1/2 phosphorylation. a Characterisation of cAMP
accumulation in response to stimulation by CGRP, AM, and AM2 with and without PTX treatment relative to forskolin (100 μM) (n= 4). b–e Characterisation
of ERK1/2 phosphorylation in response to stimulation by CGRP, AM, and AM2 with and without PTX treatment relative to PMA (10 μM) (n= 4) (b), with/
without Rp-8-Br-cAMPS (10 μM) (n= 3) (c), with/without YM-254890 (100 nM) relative to PMA (10 μM) (n= 3) (d) and with/without ESI-09 (100 μM)
(n= 3) (e). Data are analysed using a three-parameter non-linear regression curve. All data represent mean ± SEM of n independent experiments. Statistical
significance determined compared to control using an unpaired Student’s t test with Welch’s correction (*p < 0.05; **p < 0.01; ***p < 0.001). NS denotes no
statistical significance observed. Rows show pEC50, and vertical arrows show Emax statistical significance.
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the long-term cell proliferation assays (Fig. 4f and Supplementary
Table 2).
Analysis of the RAMP1-HUVEC signalling profile suggested a
close overlap with the properties of HCMs for the five different
signalling pathways as well as an opposing signalling profile to
HUVECs (Fig. 5 and Supplementary Table 2). We confirmed this
using correlation plots (Supplementary Fig. 6a–f) of both potency
and transducer coefficient Log(τ/KA), obtained from application
of the operational model of receptor agonism27 and in bias factors
(Fig. 5a, b, Supplementary Table 2, 3). Overall, our results show
that the pattern of bias seen with the CGRP receptor is robust and
is transferred between the HUVEC and HCM cell line
backgrounds.
Discussion
We have shown that the CGRP family of endogenous peptides
demonstrate biased agonism at the endogenous CLR in a phy-
siological system; and that the RAMP expressed dictates the
intracellular response and ultimately the physiological outcome.
Many receptors have been shown to demonstrate agonist bias; but
for the most part, this has been shown through synthetic ligands
designed to target certain receptor pathways2. We have now
shown that this is a process that can occur physiologically to
direct different outcomes. Through elucidating distinct patterns
of signalling bias that each peptide-receptor-RAMP produces, we
have shown that bias is a naturally occurring phenomenon in a
range of human cardiovascular cells. Furthermore, while we have
only begun to scratch the surface of how important bias is phy-
siologically, it is now clear it is an intrinsic part of endogenous
CLR function, and we anticipate this is the case for many more
GPCRs that exhibit signalling bias in over-expression studies. We
have also demonstrated the importance of studying GPCR second
messenger signalling with the endogenous receptor in its native
environment, with the distinct signalling patterns of AM2 we
have uncovered providing a good example of this.
We have confirmed, using genome editing that, as anticipated
by the co-expression models, that endogenous CLR is unable to
function without RAMP expression. This provides, to the best of
our knowledge, the first example of CRISPR-Cas9 interrogation
of GPCR function in a primary cardiovascular cell. Furthermore,
we have shown that the expression of a different RAMP in the
HUVECs can switch the signalling bias of the CLR and associated
peptide agonists, thus providing additional evidence that RAMP
targeting could become a powerful therapeutic tool31.
We have compared the pharmacology of these receptors in
terms of cAMP accumulation to reports compiling multiple
values from independent publications using the human receptor
in transfected systems22. It was reassuring therefore to observe
that CGRP, AM, and AM2 displayed similar trends in cAMP
potency at CGRP/AM1 receptors in the primary cells to those
seen in recombinant co-expression studies, as well as in the gene-
edited RAMP1-HUVECs which reflected the cAMP data from
transfected systems (Fig. 5c). In addition, we have performed a
comprehensive analysis of the mechanisms used by AM1
receptor to stimulate ERK1/2 phosphorylation in endothelial cells
(Fig. 2). It is apparent that each agonist uses unique mechanisms
to activate ERK1/2. For both CGRP and AM2 it is mediated
in a Gi/o-dependent manner, while AM uses a combination of
Gq/11/14 signalling and exchange proteins directly activated by
cAMP1/2 activation. None of the agonists appear to mediate
Fig. 3 Switching RAMP expression in HUVECs produces unique signalling bias patterns for CGRP family of agonists. a Expression of CALCR, CALCRL,
RAMP1, RAMP2, and RAMP3 genes in RAMP1 expressing HUVECs. Data normalised to GAPDH expression. n= 3 independent experiments. b–f Dose–response
curves were constructed for RAMP1 expressing HUVECs stimulated with CGRP, AM or AM2 and the cAMP levels quantified relative to forskolin (100 μM)
(n= 4) (b), mobilisation of Ca2+i relative to ionomycin (10 μM) (n= 6) (c), total NO production relative to acetylcholine (10 μM) (n= 3) (d), intracellular
ERK1/2 phosphorylation relative to PMA (10 μM) (n= 3) (e), and extent of cell proliferation (after 72 h) relative to vector treated control and VEGF (n= 4) (f).
Data are analysed using a three-parameter non-linear regression curve or the operational model of receptor agonism27. g–h Signalling bias plots were calculated
as ΔLog(τ/KA) (g) or ΔΔLog(τ/KA) (h) for each agonist and for each signalling pathway. Determination of values requires normalisation to a reference agonist
(AM) alone in (g), while for (h) values were normalised to both a reference agonist (AM) and a reference pathway (cAMP). All data represent mean ± SEM for
n repeats.
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their ERK1/2 stimulation through the so-called cognate pathway,
cAMP accumulation. The data presented is ERK1/2 phosphor-
ylation after 5 min and it will be of interest to determine the
mechanisms and spatial locations that facilitate long term ERK1/2
phosphorylation.
What has become clear in this study is that each of the
endogenous ligands has very specific potencies at each pathway
measured, whether it is at AM1 receptor in HUVECs/HUAECs or
CGRP receptors in HCMs or RAMP1-HUVEC cells. Each peptide
generates its own unique signalling profile (Fig. 5d–f). In a
concentration-dependent manner, they individually recruit dis-
tinct G proteins in a manner regulated by the RAMP. This leads
to a specific pattern of second messenger production and there-
fore a ‘signalling barcode’ for the cell to interpret and produce
further physiologically necessary downstream responses. Expres-
sion analysis reveals in our three primary cell lines that each only
expresses mRNA above the detection threshold for CLR and one
RAMP. Combined with the cAMP signalling profile for each it
appears that endothelial cells and HCM are excellent primary
model cell types for the analysis of how the AM1/CGRP receptors
signal in vivo.
It is worth noting that the present method of classifying
receptors for CGRP and AM is based upon their potencies at
cAMP production in addition to their affinities in binding
assays32. This method arose due to the assumption that cAMP
was the most physiologically relevant pathway. Here, we have
demonstrated that different potencies are observed for agonists
and these lead to physiologically relevant outcomes. As such we
need to carefully consider how we classify CGRP-related recep-
tors in the future and, more widely, all GPCRs that exhibit
agonist bias.
We can also consider this work in the wider context of the
organs and systems these cells are found in as this sheds light on
some of the pathways, and involvement of bias in some of the
established roles of CGRP family peptides in the cardiovascu-
lature. It has long been recognised that all three peptides show
pleiotropic signalling, activating multiple G proteins and signal-
ling pathways33 (and indeed this continues in current
literature34–36), but it has previously not been possible to fit this
into any framework. We suggest our current observations on
RAMP-directed bias may assist with this.
AM has a multitude of important roles in vascular homeostasis;6
one of which is regulating endothelial barrier function37. It is
thought to cause barrier stabilisation and protect against infection
mediated junctional protein disappearance, all brought about
initially through cAMP production38. This is supported by our
work demonstrating AM produces a potent cAMP response and is
biased towards this pathway. It is also well documented that AM is
a potent vasodilator known to mediate some of its vasodilatory
effects through NO release from vascular endothelial cells25,39
which we have pharmacologically profiled here.
In contrast, the precise role of AM2, which is also found in
endothelial cells, has been unclear. We now provide evidence that
AM2 is a potent stimulator of Ca2+i mobilisation and NO
synthesis. It is possible therefore that this plays a vital role at least
in umbilical endothelial cell physiology, and indeed wider vas-
cular physiology. Thus, the finding of AM2’s greater potency than
AM at eliciting NO release via Ca2+i mobilisation may have great
therapeutic potential.
Interestingly, in vascular endothelial cells CGPR inhibits ade-
nylyl cyclase through Gi/o and predominantly signals through
pERK1/2, and proliferation. The link between pERK1/2 and
Fig. 4 CGRP family peptide signalling bias in human cardiomyocytes. a Expression of CALCR, CALCRL, RAMP1, RAMP2, and RAMP3 genes in HCMs. Data
normalised to GAPDH expression. n= 3 independent experiments. b–f Dose–response curves were constructed for HCMs stimulated with CGRP, AM or
AM2 and the cAMP levels quantified relative to forskolin (100 μM) (n= 6) (b), mobilisation of Ca2+i relative to ionomycin (10 μM) (n= 4) (c), total NO
production relative to isoproterenol (10 μM) (n= 3) (d), intracellular ERK1/2 phosphorylation relative to PMA (10 μM) (n= 4) (e) and extent of cell
proliferation (after 72 h) relative to vector treated control and VEGF (n= 5) (f). Data are analysed using a three-parameter non-linear regression curve or
the operational model of receptor agonism27. g, h Signalling bias plots were calculated as ΔLog(τ/KA) (g) or ΔΔLog(τ/KA) (h) for each agonist and for
each signalling pathway. Determination of values requires normalisation to a reference agonist (AM) alone in (g), while for (h) values were normalised to
both a reference agonist (AM) and a reference pathway (cAMP). All data represent mean ± SEM for n repeats.
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cellular metabolism/proliferation is well established40–42, as well
as in endothelial cells specifically43–45. We have shown that where
an agonist has biased signalling towards ERK1/2 phosphorylation,
this is carried through to long term cellular proliferation.
Importantly, this shows overall that two non-cognate ligands,
often not considered important for receptor function, do in fact
have important signalling and physiological roles/capabilities. In
addition, we have demonstrated that endogenous pERK1/2 can
come from a variety of sources depending on the stimulating
ligand. Together this shows that CLR initiates a multitude of
intracellular pathways beyond simply Gs and cAMP/protein
kinase A in physiologically relevant cells. Therefore, our data adds
further evidence that AM for AM1 receptor and CGRP for CGRP
receptor should only be considered the cognate ligands in terms
of Gs-mediated cAMP signalling, and when looking at the phy-
siology of RAMP2 in endothelial cells and the vasculature as a
whole, CGRP and AM2 should be considered alongside AM for
their different and potentially complementary roles.
In the heart, there are multiple reports that CGRP has a cAMP-
mediated positive inotropic and chronotropic effect5,46,47, and
our data showing its strong response in cAMP accumulation
assays on human myocytes (combined with its overall bias
towards this pathway) supports this. There are contrasting reports
in the literature over AM’s effect on heart contractility;7,48 with
some suggestions that it is a positive inotrope acting in the same
cAMP driven manner as β-adrenoceptor agonists49, while others
report it having negative inotropic effects50,51. Here we show that
AM promotes a cAMP response through CGRP receptor in
human cardiomyocytes, but it has weak potency. This may pro-
vide some context/explanation for the contradictory literature
reports. Furthermore, our report has clearly revealed that cAMP
is not AM’s primary signalling pathway in HCMs and that it is
biased towards pERK1/2 and cell proliferation rather than cAMP
and positive inotropy. Nevertheless, evidence suggests that AM
has an important role in the human heart. This includes the
observed elevation of AM in the failing heart52. Here, we have
Fig. 5 CGRP signalling bias in RAMP1 expressing HUVECs correlates with that in HCMs. a Signalling bias plots were calculated as ΔΔLog(τ/KA) for
CGRP in the three cell lines, HUVECs, RAMP1 expressing HUVECs and HCMs for each pathway. Values have been normalised to a reference agonist
(AM2) and the reference pathway (cAMP) for all three cell lines. b As for (a) except the calculated values are for AM. c Log potency ratios (as measured
by the accumulation of cAMP) calculated as Log (EC50AM2/EC50 agonist). Data are compiled from12,19. HUVECs and HUAECs are shown in red and green
respectively, HCMs in cyan and RAMP1-HUVECs in blue. d–f Schematic representation of the signalling bias produced by CGPR (d), AM (e) and AM2 (f),
and the intracellular ‘signalling codes’ they bring about based on the potencies recorded at individual pathways in HUVECs, RAMP1-HUVECs, and HCMs.
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utilised proliferating human ventricular myocytes in vitro and
shown that AM (but not CGRP or AM2) exhibits signalling bias
specifically towards pERK1/2 and enhancing proliferation in these
cells. This work highlights AM as a peptide hormone that may
promote cardiac regeneration naturally in vivo and provides a
cellular mechanism for this. This may also explain the elevation of
AM in heart failure6 and the clinical trial data showing that AM
administration reduces infarct size53. For AM2, its effect on
contraction of the heart is blocked by both inhibitors of both
protein kinase A and C, suggesting multiple signalling pathways
are activated by this peptide in-vivo54. This pleiotropy in sig-
nalling pathways is also present in vascular cells, which are
themselves far from homogeneous. This may be relevant to the
heterogeneity observed in the actions of CGRP and for example,
the role of NO or other signalling pathways in vasodilation.
Indeed, CGRP has been suggested, in earlier studies, to mediate
endothelium-dependent relaxation involving NO via an unknown
endothelial receptor55. We suggest the AM1 receptor would be a
viable candidate for this ‘unknown’ receptor. It is also worth
noting that changes in RAMP expression have been observed due
to pathological changes in blood pressure and in response to drug
treatment. These will all have complex effects as a result of bias
and depending on the expression of CGRP, AM and AM256.
It should be noted that not all studies reveal pleiotropic sig-
nalling for the CGRP family of peptides57. We suggest that there
is cell membrane (e.g. lipid composition) and cell line-specific
factors (e.g. expression of G proteins) that influence the observed
bias. It is also important to consider the temporal aspects of signal
bias; in this study we have generally measured responses at what
seems to be their peak up to 30-min stimulations. However,
different patterns of bias may be observed if other time points are
selected, particularly where signalling from internalised receptors
is important.
In summary, we have gone beyond previous studies in
recombinant systems to observe agonist bias. While we have
focused upon CLR-RAMP complexes, our ability to switch the
RAMP means we are, in effect, switching the expressed receptor
and, therefore our work, has general applicability to all GPCRs.
Our data highlights how endogenous agonist bias can have pro-
found consequences for the cell and how important cell back-
ground is in regulating this process. This work may even go as far
as to suggest that to fully understand bias at a GPCR, it must be
considered in its native environment. While our work takes an
important step closer to understanding how the CGRP family of
peptides and receptors function on a cellular level in the human
cardiovascular system, it also highlights the importance of
endogenous agonist bias as a concept and emphasises its long-
term consequences for drug design.
Materials and methods
Cell culture. HUVECs and HUAECs (were both sourced from PromoCell, Germany;
C-12250 and C-12252 respectfully) were cultured in Endothelial Cell Growth Media
(ECGM) (PromoCell). Human Cardiac Myocytes (PromoCell, C-12811) were grown
in Cardiac Myocyte Growth Media (CMGM) (PromoCell). All cell lines were cultured
in media containing 10% heat inactivated Foetal Bovine Serum (FBS) (Sigma, USA).
Cells were grown in 25 cm2 flasks or 75 cm2 flasks depending on cell density required.
They were passaged approximately every 4 days depending on confluency with a final
volume of 10ml produced from 1ml of the previous cell culture and 9ml of the
growth medium in 75 cm2 flasks, or 1 ml using 4ml in 25 cm2 flasks, and used from
passage 2–6 (with the exception of HUVECΔRAMP2 and RAMP1-HUVEC). All cells
were grown with 1% antibiotic antimycotic solution (100x Sigma, USA). The cells
were maintained in an incubator (37 °C, humidified 95% air, 5% CO2) between
passaging.
Genome engineering. HUVECs with the RAMP2 gene knocked out were gener-
ated by CRISPR/Cas9 homology-directed repair as described previously58. We
chose the HUVEC cell line with which to perform the gene editing since we have
been able to grow HUVECs beyond passage 6 to passage 14 before loss of CGRP
based signalling responses are observed (Supplementary Fig. 7), and it is necessary
to grow them past passage 6 to develop the RAMP2 null cells. We used a pooled
sgRNA strategy using three sgRNAs in separate lentivirus (Supplementary Fig. 4a)
which were selected using a puromycin resistance cassette (Supplementary Fig. 4b)
to increase our efficiency of editing. The sgRNA sequences were designed (5′-CGC
TCCGGGTGGAGCGCGCCGG-3′), (5′-TCCGGGTGGAGCGCGCCGGCGG-3′),
and (5′-CCCGCGTCTCCCTAGGACCCGA-3′) for Cas9 targeting to the human
RAMP2 gene (Sigma, US). All guides were delivered in the LV01 vector (U6-gRNA:
ef1a-puro-2A-Cas9-2A-tGFP) vector provided by (Sigma-Aldrich, US). Sequences
were verified by Sanger sequencing. The control cell line was established by
transduction of LV01 vector not containing sgRNA targeted to RAMP2 gene.
HUVEC cells were seeded in 6 well plates at a cell density of 160,000 cells/well and
maintained at 37 °C in 5% CO2 with Complete Endothelial Cell Growth Media
containing 100 μg/ml streptomycin (Sigma-Aldrich, US). 24 h after seeding virus
containing individual sgRNA/Cas9 constructs were pooled and transduced into
cells at a high multiplicity of infection of 10, ensuring that each cell is infected by
several lentivirus and increasing the likelihood of achieving knockout. Transduc-
tion was performed in media containing 8 μg/ml Polybrene (Sigma, USA). Cells
were cultured for 24 h then treated with Puromycin (1 μg/ml) (Thermo Fisher
Scientific, UK) for 3 days to select for transduced cells. Cells then cultured without
puromycin and expanded before cells were collected for genotyping by Sanger
sequencing, qRT-PCR, and functional assays. All data shown were from cells
expanded from these colonies. RAMP1 expression achieved through transduction
of virus containing RAMP1 MISSION TRC3 ORF plasmid (pLX_304) (Sigma, US)
into HUVEC-ΔRAMP2. HUVEC cells were seeded in 6 well plates at a cell density
of 160,000 cells/well and maintained at 37 °C in 5% CO2 with Complete Endo-
thelial Cell Growth Media containing 100 μg/ml streptomycin (Sigma, US). 24 h
after seeding, virus containing the ORF construct was transduced into cells in
media containing 8 μg/ml Polybrene. Cells were cultured for 24 h then treated with
blasticidin (5 μg/ml) (Thermo Fisher Scientific, UK) for 6 days to select for
transduced cells. Cells were collected for genotyping by qRT-PCR and expanded
for functional assays. All ‘HUVEC-RAMP1’ data shown were from cells expanded
from these colonies.
Immunofluorescence. HUVEC cells were seeded in Cell Carrier Ultra 96-well
plate (PerkinElmer, Boston, MA, US) at a cell density of 160,000 cells/well and
maintained at 37 °C in 5% CO2 with Complete Endothelial Cell Growth Media
containing 100 μg/ml streptomycin. Cells were washed twice with PBS, fixed with
4% paraformaldehyde in PBS (10 min, room temperature) then washed three times
with PBS. The cells were permeabilized with 0.05% Tween 20 in PBS (60 min, room
temperature), and then incubated with 10% goat serum in PBS (60 min, room
temperature). The cells were then incubated in primary antibody for Cas9 protein
(Cell signalling technology, MA, US) 7A9-3A3, diluted 1/700 in PBS/0.05% Tween/
3% BSA) at 4 °C, overnight and protected from light. The cells were washed three
times with PBS and incubated with AlexaFluor 488 goat anti-mouse (Invitrogen
A11001, 1/500) (1 h, room temperature) protected from light. Cells were washed
three times with PBS, then nuclei were stained with Hoechst (Invitrogen) (1/2000
in PBS, 10 min, room temperature). Cells were then washed three times with PBS
w/o Mg2+ or Ca2+i and imaged at 20x magnification (Cell Voyager 7000 S,
Yokogawa).
Sequencing of genomic loci. Genomic DNA was extracted from virally transduced
HUVEC cells by: collecting approximately 10,000 cells, washing in PBS (sigma-Aldrich,
US) and then lysing with DirectPCR Lysis Reagent (Viagen Biotech, US) containing
Proteinase K (Qiagen, Germany) at 0.4mg/ml. The lysate was incubated at 55 °C for
4 h; 85 °C, for 10min; 12 °C for 12 h. PCR reaction was then set up in (20 μl) as follows:
2x Flash Phusion PCR Master Mix (Thermo Fisher, US) (20 μl), forward primer (5′-
AATTCGGGGAGCGATCCTG -3′) (Eurogentec, Belgium) (1 μl)(10μm), reverse pri-
mer (5′- GAGACCCTCCGAAAATAGGC -3′) (Eurogentec, Belgium) (1 μl)(10μm),
DNA (100 ng/μl)(1 μl), ddH2O (7 μl). The product was amplified by PCR using the
following programme: 98 °C, 1min; 35 x (98 °C, 10 s; 55 °C, 10 s; 72 °C, 15 s), 72 °C,
1min; 4 °C, hold. PCR clean-up was performed prior to sequencing using the Illustra
GFX PCR DNA and Gel-band Purification Kit (Illustra, Germany) according to the
manufacturer’s instructions. Editing of RAMP2 gene was confirmed by Sanger
sequencing (Eurofins–Supplementary Fig. 4c, d 1, Supplementary data 3, 4) and TIDE
analysis30.
Quantitative real-time reverse transcription polymerase chain reaction (qRT-
PCR). HUVECs were cultured as above in Complete Endothelial Cell Growth
medium and plated in a 24-well plate at 100,000 cells/well. Media was then
removed, and cells were washed in PBS (Sigma, UK). RNA was extracted and
genomic DNA eliminated using an RNA extraction kit (Qiagen, Germany) as per
the manufacturer’s instructions. The yield and quality of RNA were assessed by
measuring absorbance at 260 and 280 nm (Nanodrop ND-1000 Spectro-
photometer, NanoDrop technologies LLC, Wilmington DE USA). RNA was used
immediately for the preparation of cDNA using the Multiscribe reverse tran-
scriptase. For the preparation of cDNA 100 ng of RNA was reverse transcribed
using Taq-man reverse transcription kit (Life Technology, MA, USA) according to
the manufacturer’s instructions. Reactions were performed on a thermal Cycler as
following: 25 °C, 10 min; 48 °C, 30 min; 95 °C, 5 min. cDNA was stored at −20 °C.
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For each independent sample, qPCR was performed using TaqMan Gene
Expression assays according to the manufacturer’s instructions (Life Technologies,
MA, USA) for GAPDH, CALCR, CALCRL, RAMP1, RAMP2, RAMP3, all Gɑ
subunits and β-arrestins were plated onto fast microAmp plates containing 2 μl
cDNA, 1 μl Taq-man probe, 10 μl Taq-man fast universal master mix (Applied
Biosystems) and 10 μl ddH2O. Oligonuclotides used were as described in Weston
et al.19 and Routledge et al.59. For β-arrestin1 forward primer (5′-AAAGGGAC
CCGAGTGTTCAAG-3′) (Thermo Fisher, US), reverse primer (5′–CGTCACA
TAGACTCTCCGCT-3′) and β-arrestin2 forward primer (5′–TCCATGCTCC
GTCACACTG-3′), reverse primer (5′–ACAGAAGGCTCGAATCTCAAAG-3′).
PCR reactions were performed on ABI 7900 HT real time PCR system (Thermo
Fisher Scientific, UK). The programme involved the following stages: 50 °C, 2 min;
95 °C, 10 min, the fluorescence detection over the course of 40x (95 °C, 15 s; 60 °C,
1min). Data are expressed as relative expression of the gene of interest to the
reference gene GAPDH where: Relative expression= 2-((Cq of gene of interest)− (Cq
of GAPDH)).
In vivo assays
Measurement of intracellular cAMP. All primary cell lines were cultured as above.
On the day of the experiment media was removed and cells washed with PBS,
before being dissociated with Trypsin-EDTA 0.05% (Gibco, UK) and then resus-
pended in PBS/BSA (0.1%) (Sigma, UK). Cells were immediately plated for use in
cAMP assay as per the manufacturer’s instructions, reagents used were provided by
the LANCE® cAMP detection assay kit (PerkinElmer, Boston, MA, USA), in 384
well optiplates (PerkinElmer (Boston, MA, USA)) at 2000 cells/well in 5 μl
aliquots19. Human (h) αCGRP, hAM and hAM2 (Bachem, Switzerland) were
diluted in PBS/BSA (0.1%) with 250 μM 3-Isobutyl-1-methylxanthine (Sigma, UK),
and used from 10 pM to 10 μM. Cells were incubated with compound for 30 min
prior to adding detection buffer28,60. Plates were incubated for a further 60 min
(room temperature) and then read on a plate reader (Mithras LB 940 microplate
reader (Berthold technologies, Germany)). All responses were normalised to
100μM forskolin (Tocris, UK). Antagonist studies were performed in the same way
through co-stimulation of the relevant concentration. Alongside control-treated
cell. Experiments with PTX (Sigma, UK) required pretreatment (16 h) prior to
assays.
Measurement of Phospho-ERK1/2 (Thr202/Tyr204). Primary cells were grown in 6
well plates, on the day of the experiment media was replaced with serum free media
4 h prior to cell harvesting. Tyrpsin-EDTA was used to dissociate the cells and they
were collected by centrifugation, counted and re-suspended HBSS/BSA (0.1%).
Ligands were also diluted in HBSS/BSA. Cells were then plated on 384 well plates
in 8 μl aliquots at a density of 20,000 cells/well. Next, ligands were added (4 μl) for
5 min stimulation at room temperature. Cells were then lysed as per to the man-
ufacturer’s instructions with 4 μl of lysis buffer (Cisbio phosphor-ERK1/2 cellular
assay kit, Invitrogen, UK) for 30 min shaking at room temperature. The 2 specific
antibodies; were pre-mixed in a 1:1 ratio. 4 μl of this was added to each well and the
plate incubated for a further 2 h. Then fluorescence emissions were read at 665 nm
and 620 nm using a Mithras LB940 microplate reader. Antagonist studies were
performed in the same way through co-stimulation with PTX (200 ng/ml), Rp-8-
Br-cAMPS (100 μM), YM-254890 (100 nM), or ESI-09 (100 μM) as appropriate
alongside control-treated cell.
Measurement of Intracellular Calcium mobilisation. All cell lines were plated at
20,000 cells/well on 96-well black clear-bottom plates (Costar, UK) 24 h before the
experiment. Media was removed, and cells were washed with Hank’s Balance Salt
Solution (HBSS) (Lonza, Switzerland) before cells were loaded with 10 μM Fluo-4/
AM (Invitrogen, US) in the dark at room temperature for 30 min. Cells were then
washed twice with calcium-free HBSS, then were left in 100 μl calcium-free HBSS
for the duration of the assay. In conditions where Gαq/11/14 signalling is inhibited,
cells were pre-treated with 100 nM YM-254890 (Alpha Laboratories, UK) (30
min)22. All assays were performed using the BD Pathway 855 Bioimaging Systems
(BD Biosciences, UK), which dispenses ligands (20 μl) and reads immediately for
2 min. Data was normalised to the response seen with 10 μM Ionomycin.
Measurement of cell proliferation. Both endothelial cell lines and HCMs were
seeded at a density of 2500 cells/well in a clear flat bottom 96-well plate (Corning,
UK) and incubated at 37 °C in 5% CO2. After 24 h, cells were exposed to test
compounds or vehicle, in complete endothelial cell growth media (HUVECs) or
myocyte growth media (HCMs). Cells were incubated for a further 72 h at 37 °C in
5% CO2. After 72 h incubation, 5 μl of Cell Counting Kit–8 (CCK-8, Sigma, UK)
was added to each well and cells were then incubated for another 2 h at 37 °C in 5%
CO2 and in the dark61. The absorbance of each well was measured using a Mithras
LB940 microplate reader with an excitation of 450 nm. The absorbance is directly
proportional to the number of viable cells. Cell proliferation was calculated as a
percentage of number of cells treated with vehicle alone.
Measurement of nitric oxide production. Endothelial cells and HCMs were cultured
as above. 24 h prior to assay cells were plated on Costar 96-well black clear bottom
plates at 40,000 cells/well. The assay was performed according to the
manufacturer’s protocol. Briefly, cells pre-incubated with NO dye and assay
buffer 1 (Fluorometric Nitric Oxide Assay Kit, Abcam, UK) for 30 min at 37 °C in
5% CO2. Any inhibitors requiring 30 min pre-treatment (YM/L-NAME/DMSO
control) were added at this point. Ligand stimulation occurred immediately
after this for 15 min at 37 °C in 5% CO2. Stain and ligand solution was removed,
assay buffer II was added, and wells were read immediately. The absorbance was
measured using a Tecan T200 (Thermo Fisher Scientific UK) reader with an
excitation/emission of 540/590 nm. Endothelial cell responses were normalised to
10 μM acetylcholine62. HCM responses were normalised to 10 μM
isoproterenol63,64.
Statistics and reproducibility. All sample sizes were determined, and data ana-
lysed, in accordance with the guidelines described by Curtis M et al.65. All
experiments were appropriately controlled using ‘system pathway’ agonists. If any
of these pathway controls generated inappropriate responses, then the entire data
set was removed from analysis. Tolerance for variation was <3-fold changes in
potency for the system parameters tested. Data analysis for cAMP accumulation,
Ca2+i mobilisation, NO accumulation, pERK1/2 activation, and cell proliferation
assays were performed in GraphPad Prism 8.4 (GraphPad Software, San Diego).
Data were fitted to obtain concentration–response curves using either the three-
parameter logistic equation using to obtain values of Emax and pEC50 or the
operational model of agonism27. Statistical differences were analysed using one-
way ANOVA followed by Dunnett’s post-hoc (for comparisons amongst more than
two groups) or unpaired Student’s t test with Welch’s correction (for comparison
between two groups). To account for the day-to-day variation experienced from the
cultured cells, we used the maximal level of cAMP accumulation from cells in
response to 100 μM forskolin stimulation was used as a reference, 10 μM iono-
mycin for Ca2+i assays, 10 μM phorbol 12-myristate 13-acetate (PMA) for pERK1/2
activation, 10 μM acetylcholine for NO production and 10 μM VEGF for cell
proliferation. Emax values from these curves are reported as a percentage of these
controls, and all statistical analysis has been performed on these data. Where
appropriate the operational model for receptor agonism27 was used to obtain
efficacy (τ) and equilibrium disassociation constant (KA) values. In both cases, this
normalisation removes the variation due to differences in days but retains the
variance for control values. The means of individual experiments were combined to
generate the curves shown. Having obtained values for τ and KA these were then
used to quantify signalling bias as the change in Log(τ/KA)19,28. Error for this






Where, SEMA and SEMB are the standard error of measurement A and B.
Correlations between pEC50 values or transducer coefficients Log (τ/KA) were
assessed by scatter plot and Pearson’s correlation coefficient (r) was calculated with
95% confidence interval.
Reporting Summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
Sequencing data is available in Supplementary Data 3, 4. Source data for the graphs and
charts in the main figures are given as Supplementary Data 1, 2 and 5–7. Any remaining
information including the primary data for all pharmacological investigations is available
from the corresponding authors on reasonable request.
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